Literature DB >> 27824604

Shorter treatment for multidrug-resistant tuberculosis: the good, the bad and the ugly.

Richard van Altena1, Onno W Akkerman1, Jan-Willem C Alffenaar2, Huib A M Kerstjens1, Cecile Magis-Escurra3, Martin J Boeree3, Dick van Soolingen4,5, Wiel C M de Lange1, Mathieu S Bolhuis2, Wouter Hoefsloot3, Gerard de Vries6,7, Tjip S van der Werf8,9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27824604     DOI： 10.1183/13993003.01208-2016

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  4 in total

1.  Case Report: Carbapenemase-Producing Enterobacteriaceae in an Asylum Seeker with Multidrug-Resistant Tuberculosis.

Authors:  Sofanne J Ravensbergen; Christina Louka; Mariëtte Lokate; Erik Bathoorn; Spyros Pournaras; Tjip S van der Werf; Wiel C M de Lange; Ymkje Stienstra; Onno W Akkerman
Journal:  Am J Trop Med Hyg       Date:  2017-12-21       Impact factor: 2.345

Review 2.  Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs.

Authors:  Johanna Kuhlin; Marieke G G Sturkenboom; Samiksha Ghimire; Ioana Margineanu; Simone H J van den Elsen; Noviana Simbar; Onno W Akkerman; Erwin M Jongedijk; Remco A Koster; Judith Bruchfeld; Daan J Touw; Jan-Willem C Alffenaar
Journal:  Clin Mass Spectrom       Date:  2018-10-19

3.  Treatment outcomes of drug-resistant tuberculosis in the Netherlands, 2005-2015.

Authors:  Ivan S Pradipta; Natasha Van't Boveneind-Vrubleuskaya; Onno W Akkerman; Jan-Willem C Alffenaar; Eelko Hak
Journal:  Antimicrob Resist Infect Control       Date:  2019-07-12       Impact factor: 4.887

4.  Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis.

Authors:  Onno W Akkerman; Floris Grasmeijer; Wiel C M de Lange; Huib A M Kerstjens; Gerard de Vries; Mathieu S Bolhuis; Jan-Willem Alffenaar; Henderik W Frijlink; Grace Smith; Roger Gajraj; Rina de Zwaan; Paul Hagedoorn; Martin Dedicoat; Dick van Soolingen; Tjip S van der Werf
Journal:  Eur Respir J       Date:  2018-03-22       Impact factor: 16.671
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.